BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/11/2022 12:39:21 AM | Browse: 304 | Download: 705
 |
Received |
|
2021-08-26 04:49 |
|
Peer-Review Started |
|
2021-08-26 04:51 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-10-29 03:42 |
|
Revised |
|
2021-11-12 08:55 |
|
Second Decision |
|
2022-02-09 06:03 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-02-10 10:32 |
|
Articles in Press |
|
2022-02-10 10:32 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-01-17 03:41 |
|
Typeset the Manuscript |
|
2022-02-27 12:17 |
|
Publish the Manuscript Online |
|
2022-03-11 00:39 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Lian-Fang Liu, Jia-Ying Deng, Analyn Lizaso, Jing Lin and Si Sun |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Key R&D Program of China |
2017YFC0907900 |
| National Key R&D Program of China |
2017YFC0907904 |
|
| Corresponding Author |
Si Sun, MD, Chief Doctor, Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, No. 270 Dong An Road, Shanghai 200032, China. sunsi123sun@hotmail.com |
| Key Words |
Poorly differentiated; Non-small cell carcinoma; Mesenchymal-epithelial transition factor fusion; Crizotinib; Case report |
| Core Tip |
The most common mesenchymal-epithelial transition factor (MET) gene aberrations are gene amplifications and exon 14 splice variants found in approximately 2% to 10% of lung cancer patients. Chromosomal rearrangements resulting in gene fusions involving MET are generally rare but could account for MET-driven oncogenesis. The rarity and diversity of MET fusions in non-small cell lung cancer (NSCLC) limit the volume of evidence documenting the clinical efficacy of crizotinib in treating MET-rearranged NSCLC patients. Herein, we report the clinical response to crizotinib of a patient with advanced poorly differentiated NSCLC harboring concurrent MET-involving rearrangements, including a novel MET-CDR2 gene fusion. |
| Publish Date |
2022-03-11 00:39 |
| Citation |
Liu LF, Deng JY, Lizaso A, Lin J, Sun S. Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report. World J Clin Cases 2022; 10(8): 2529-2536 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i8/2529.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i8.2529 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
